Eupraxia Pharmaceuticals Secures Board Approval at Annual General Meeting

Eupraxia Pharmaceuticals Inc. (TSX: EPRX, NASDAQ: EPRX), a clinical-stage biotechnology company, announced the results of its Annual General Meeting of Shareholders (AGM) held on June 18, 2026. The company reported that shareholders elected all seven director nominees proposed by management and re-appointed KPMG LLP as the auditor for the upcoming year. These voting outcomes demonstrate continued stability in the company's corporate governance.

At the meeting, each of the seven nominees proposed for election to the Board of Directors received a significant majority of shareholder votes. According to the disclosed results, the candidates garnered over 91% support. For instance, James A. Helliwell was elected with 99.784% of votes, Simon Pimstone with 91.102%, Richard M. Glickman with 97.915%, John Montalbano with 98.047%, Joseph Freedman with 99.849%, Amy Pott with 99.850%, and Robert Bazemore with 99.975%. Additionally, the re-appointment of KPMG LLP as the company's auditor was also approved by shareholders at the general meeting.

These AGM results signify ongoing corporate stability for Eupraxia Pharmaceuticals and indicate strong shareholder support for the current management team. As a clinical-stage biotechnology company, Eupraxia focuses on optimizing local, controlled drug delivery through its proprietary Diffusphere™ technology. The company is advancing its Phase 1b/2a RESOLVE trial for EP-104GI in the treatment of eosinophilic esophagitis (EoE) and has successfully completed the Phase 2b SPRINGBOARD clinical trial of EP-104IAR for pain due to knee osteoarthritis.

In the biotechnology sector, a strong and stable board of directors is crucial given the long-term nature of research and development (R&D) processes and the complexities of regulatory approvals. The re-election of Eupraxia's board reinforces expectations that the company's current strategic direction and clinical programs will proceed without interruption. This situation could bolster investor confidence, particularly concerning the success of clinical trials and the development of the Diffusphere™ platform.

This robust shareholder endorsement for management provides a solid foundation for the company's future growth and R&D investments. Market participants may view such corporate stability as a positive factor in the company's ability to achieve its operational goals, especially in a capital-intensive and risky sector like biotechnology. Moving forward, data from Eupraxia's ongoing clinical trials and its product development roadmap will remain a key focus for investors.